nach oben

Erschienen in:

21.02.2018 | Original Research

Prognostic Factors and the Role of Adjuvant Treatment in Periampullary Carcinoma: a Single-Centre Experience of 95 Patients

verfasst von: Saphalta Baghmar, Nikhil Agrawal, Guresh Kumar, Chhagan Bihari, Yashwant Patidar, Senthil Kumar, Tushar Kanti Chattopadhyay, Dipanjan Panda, Asit Arora, Viniyendra Pamecha

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The effect of adjuvant treatment on those undergoing pancreaticoduodenectomy (PD) for periampullary carcinomas (PAC) is not well studied. Most studies employed chemoradiation as the adjuvant modality. We aimed to analyse clinicopathological differences between types of PACs, the prognostic factors and the role of adjuvant therapy (chemotherapy in the majority).

Methods

Patients with PAC who underwent PD from Jan 2011 to Dec 2015 were retrospectively analysed.

Results

Ninety-five patients with PAC underwent PD in the study period. Ampullary carcinoma (AC) was the most common. Pancreatic carcinomas (PC) were larger. AC had lower T stage, perineural invasion (PNI) and R1 resections. Median overall survival (OS) was 32.7 months. On multivariate analysis, lymph node ratio (LNR) ≥ 0.2 and advanced T stage adversely affected the OS. Fifty-seven (66.3%) patients received adjuvant treatment, of which 50 had chemotherapy alone. Adjuvant treatment resulted in better OS in patients with T stage ≥ 3, lymph node involvement, LNR ≥ 0.2, lymphovascular invasion, PNI, tumour size > 2 cm, higher grade and distal cholangiocarcinoma.

Conclusion

In patients of PAC undergoing PD, AC had favourable clinicopathological profile. LNR ≥ 0.2 and advanced T stage adversely affected OS. Adjuvant treatment resulted in significantly better OS in patients with high-risk features.

Berberat PO, Künzli BM, Gulbinas A, Ramanauskas T, Kleeff J, Müller MW, et al. An audit of outcomes of a series of periampullary carcinomas. Eur J Surg Oncol. 2009 Feb;35(2):187–91. https://doi.org/10.1016/j.ejso.2008.01.030.

Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Lillemoe KD, Pitt HA. Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg. 1998 Jun;227(6):821–31. https://doi.org/10.1097/00000658-199806000-00005.CrossRefPubMedPubMedCentral

Kim K, Chie EK, Jang J-Y, Kim SW, Han S-W, Oh D-Y, et al. Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma. Clin Transl Oncol. 2012 May;14(5):391–5. https://doi.org/10.1007/s12094-012-0814-2.

Zhao X, Dong J, Huang X, Zhang W, Jiang K. Prognostic factors for survival of patients with ampullary carcinoma after local resection. ANZ J Surg. 2015 Jul 1;85(7–8):567–71. https://doi.org/10.1111/ans.12600.CrossRefPubMed

Chen S-C, Shyr Y-M, Wang S-E. Longterm survival after pancreaticoduodenectomy for periampullary adenocarcinomas. HPB. 2013 Dec;15(12):951–7. https://doi.org/10.1111/hpb.12071.CrossRefPubMedPubMedCentral

Abdullah SA, Gupta T, Jaafar KA, Chung YFA, Ooi LLPJ, Mesenas SJ. Ampullary carcinoma: effect of preoperative biliary drainage on surgical outcome. World J Gastroenterol. 2009 Jun 21;15(23):2908–12. https://doi.org/10.3748/wjg.15.2908.CrossRefPubMedPubMedCentral

Falconi M, Crippa S, Domínguez I, Barugola G, Capelli P, Marcucci S, et al. Prognostic relevance of lymph node ratio and number of resected nodes after curative resection of ampulla of Vater carcinoma. Ann Surg Oncol. 2008 Nov;15(11):3178–86. https://doi.org/10.1245/s10434-008-0099-4.

Şeren TD, Topgül K, Koca B, Erzurumlu K. Factors affecting survival in patients who underwent pancreaticoduodenectomy for periampullary cancers. Ulusal Cerrahi Derg. 2015;31(2):72.

Robert P-E, Leux C, Ouaissi M, Miguet M, Paye F, Merdrignac A, et al. Predictors of long-term survival following resection for ampullary carcinoma: a large retrospective French multicentric study. Pancreas. 2014 Jul;43(5):692–7. https://doi.org/10.1097/MPA.0000000000000112.

10.

Kim WS, Choi DW, Choi SH, Heo JS, You DD, Lee HG. Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer. J Surg Oncol. 2012 Mar;105(3):266–72. https://doi.org/10.1002/jso.22090.CrossRefPubMed

11.

Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010 Jun;17(6):1471–4. https://doi.org/10.1245/s10434-010-0985-4.CrossRef

12.

Protocol for the Examination of Specimens From Patients With Carcinoma of the Exocrine Pancreas (www.cap.org) IL: College of American Pathologists; 2016.

13.

He J, Ahuja N, Makary MA, Cameron JL, Eckhauser FE, Choti MA, et al. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. HPB. 2014 Jan;16(1):83–90. https://doi.org/10.1111/hpb.12078.

14.

Williams JL, Chan CK, Toste PA, Elliott IA, Vasquez CR, Sunjaya DB, et al. Association of histopathologic phenotype of periampullary adenocarcinomas with survival. JAMA Surg 2017 Jan 1;152(1):82–88.

15.

Perrone G, Santini D, Zagami M, Vincenzi B, Verzì A, Morini S, et al. COX-2 expression of ampullary carcinoma: correlation with different histotypes and clinicopathological parameters. Virchows Arch Int J Pathol. 2006 Sep;449(3):334–40.CrossRef

16.

Ruemmele P, Dietmaier W, Terracciano L, Tornillo L, Bataille F, Kaiser A, et al. Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions. Am J Surg Pathol. 2009 May;33(5):691–704. https://doi.org/10.1097/PAS.0b013e3181983ef7.

17.

Sarmiento JM, Nagomey DM, Sarr MG, Farnell MB. Periampullary cancers: are there differences? Surg Clin North Am. 2001 Jun;81(3):543–55. https://doi.org/10.1016/S0039-6109(05)70142-0.CrossRef

18.

Sommerville C a. M, Limongelli P, Pai M, Ahmad R, Stamp G, Habib NA, et al. Survival analysis after pancreatic resection for ampullary and pancreatic head carcinoma: an analysis of clinicopathological factors. J Surg Oncol 2009 Dec 15;100(8):651–656, DOI: https://doi.org/10.1002/jso.21390.

19.

Ehehalt F, Rümmele P, Kersting S, Lang-Schwarz C, Rückert F, Hartmann A, Dietmaier W, Terracciano L, Aust de, Jahnke B, Saeger HD, Pilarsky C, Grützmann R Hepatocyte nuclear factor (HNF) 4α expression distinguishes ampullary cancer subtypes and prognosis after resection. Ann Surg 2011 Aug;254(2):302–310, DOI: https://doi.org/10.1097/SLA.0b013e31821994a8.

20.

Klein F, Jacob D, Bahra M, Pelzer U, Puhl G, Krannich A, et al. Prognostic factors for long-term survival in patients with ampullary carcinoma: the results of a 15-year observation period after pancreaticoduodenectomy. HPB Surg World J Hepatic Pancreat Biliary Surg. 2014;2014:970234.

21.

Bronsert P, Kohler I, Werner M, Makowiec F, Kuesters S, Hoeppner J, et al. Intestinal-type of differentiation predicts favourable overall survival: confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary, ampullary and duodenal origin. BMC Cancer. 2013 Sep 22;13(1):428. https://doi.org/10.1186/1471-2407-13-428.

22.

Westgaard A, Tafjord S, Farstad IN, Cvancarova M, Eide TJ, Mathisen O, et al. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer. 2008;8(1):170. https://doi.org/10.1186/1471-2407-8-170.

23.

Ethun CG, Lopez-Aguiar AG, Pawlik TM, Poultsides G, Idrees K, Fields RC, Weber SM, Cho C, Martin RC, Scoggins CR, Shen P, Schmidt C, Hatzaras I, Bentrem D, Ahmad S, Abbott D, Kim HJ, Merchant N, Staley CA, Kooby da, Maithel SK Distal cholangiocarcinoma and pancreas adenocarcinoma: are they really the same disease? A 13-institution study from the US extrahepatic biliary malignancy consortium and the central pancreas consortium. J Am Coll Surg 2017 Apr 1;224(4):406–413, DOI: https://doi.org/10.1016/j.jamcollsurg.2016.12.006.

24.

Serrano PE, Kim D, Kim PT, Greig PD, Moulton C-A, Gallinger S, et al. Effect of pancreatic fistula on recurrence and long-term prognosis of periampullary adenocarcinomas after pancreaticoduodenectomy. Am Surg. 2016 Dec 1;82(12):1187–95.

25.

Suzuki S, Kajiyama H, Shimoda M, Shimazaki J, Koike N, Harada N. Prognostic factors associated with preoperative clinicophysiological outcomes of distal cholangiocarcinoma. Dig Surg. 2017 Feb 7;

26.

Bourgouin S, Ewald J, Mancini J, Moutardier V, Delpero J-R, Le Treut Y-P. Disease-free survival following resection in non-ductal periampullary cancers: a retrospective multicenter analysis. Int J Surg Lond Engl. 2017 Apr 28;42:103–9. https://doi.org/10.1016/j.ijsu.2017.04.051.CrossRef

27.

Courtin-Tanguy L, Rayar M, Bergeat D, Merdrignac A, Harnoy Y, Boudjema K, et al. The true prognosis of resected distal cholangiocarcinoma. J Surg Oncol. 2016 Apr;113(5):575–80. https://doi.org/10.1002/jso.24165.

28.

Buchbjerg T, Fristrup C, Mortensen MB. The incidence and prognosis of true duodenal carcinomas. Surg Oncol. 2015 Jun;24(2):110–6.CrossRefPubMed

29.

Farid SG, Falk GA, Joyce D, Chalikonda S, Walsh RM, Smith AM, et al. Prognostic value of the lymph node ratio after resection of periampullary carcinomas. HPB. 2014 Jun;16(6):582–91. https://doi.org/10.1111/j.1477-2574.2012.00614.x.

30.

Andrianello S, Paiella S, Allegrini V, Ramera M, Pulvirenti A, Malleo G, et al. Pancreaticoduodenectomy for distal cholangiocarcinoma: surgical results, prognostic factors, and long-term follow-up. Langenbeck's Arch Surg. 2015 Jul;400(5):623–8. https://doi.org/10.1007/s00423-015-1320-0.

31.

Poultsides GA, Huang LC, Cameron JL, Tuli R, Lan L, Hruban RH, et al. Duodenal adenocarcinoma: clinicopathologic analysis and implications for treatment. Ann Surg Oncol. 2012 Jun;19(6):1928–35. https://doi.org/10.1245/s10434-011-2168-3.

32.

Hatzaras I, George N, Muscarella P, Melvin WS, Ellison EC, Bloomston M. Predictors of survival in periampullary cancers following pancreaticoduodenectomy. Ann Surg Oncol. 2010 Apr;17(4):991–7. https://doi.org/10.1245/s10434-009-0883-9.CrossRefPubMedPubMedCentral

33.

Bucher P, Chassot G, Durmishi Y, Ris F, Long-term MP. Results of surgical treatment of Vater’s ampulla neoplasms. Hepato-Gastroenterology. 2007 Jun;54(76):1239–42.PubMed

34.

Di Giorgio A, Alfieri S, Rotondi F, Prete F, Di Miceli D, Ridolfini MP, et al. Pancreatoduodenectomy for tumors of Vater’s ampulla: report on 94 consecutive patients. World J Surg. 2005 Apr;29(4):513–8. https://doi.org/10.1007/s00268-004-7498-x.CrossRefPubMed

35.

Vollmer CM, Sanchez N, Gondek S, McAuliffe J, Kent TS, Christein JD, et al. A root-cause analysis of mortality following major pancreatectomy. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2012 Jan;16(1):89–102; discussion 102-103. https://doi.org/10.1007/s11605-011-1753-x.

36.

Kang SP, Saif MW. Ampullary and Periampullary tumors: translational efforts to meet a challenge in diagnosis and treatment. Highlights from the “2011 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 20-22, 2011. JOP J Pancreas 2011 Mar 9;12(2):123–125.

37.

Narang AK, Miller RC, Hsu CC, Bhatia S, Pawlik TM, Laheru D, et al. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Radiat Oncol Lond Engl. 2011 Sep 28;6(1):126. https://doi.org/10.1186/1748-717X-6-126.

38.

Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, AC MD, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11;308(2):147–56. https://doi.org/10.1001/jama.2012.7352.CrossRefPubMed

39.

Kim K, Chie EK, Jang J-Y, Kim SW, Oh D-Y, Im S-A, et al. Role of adjuvant chemoradiotherapy for ampulla of Vater cancer. Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):436–41. https://doi.org/10.1016/j.ijrobp.2008.11.067.

40.

Kwon J, Kim BH, Kim K, Chie EK, Ha SW. Survival benefit of adjuvant chemoradiotherapy in patients with ampulla of Vater cancer: a systematic review and meta-analysis. Ann Surg. 2015 Jul;262(1):47–52. https://doi.org/10.1097/SLA.0000000000001182.CrossRefPubMed

41.

Zhou J, Hsu CC, Winter JM, Pawlik TM, Laheru D, Hughes MA, et al. Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2009 Aug;92(2):244–8. https://doi.org/10.1016/j.radonc.2009.05.006.

42.

Sikora SS, Balachandran P, Dimri K, Rastogi N, Kumar A, Saxena R, et al. Adjuvant chemo-radiotherapy in ampullary cancers. Eur J Surg Oncol. 2005 Mar;31(2):158–63. https://doi.org/10.1016/j.ejso.2004.08.013.

43.

Miura JT, Jayakrishnan TT, Amini A, Johnston FM, Tsai S, Erickson B, et al. Defining the role of adjuvant external beam radiotherapy on resected adenocarcinoma of the ampulla of vater. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2014 Nov;18(11):2003–8. https://doi.org/10.1007/s11605-014-2629-7.

44.

Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999 Dec;230(6):776–82; discussion 782-784. https://doi.org/10.1097/00000658-199912000-00006.

45.

Acharya A, Markar SR, Sodergren MH, Malietzis G, Darzi A, Athanasiou T, et al. Meta-analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma. Br J Surg. 2017 Jun;104(7):814–22. https://doi.org/10.1002/bjs.10563.

46.

Menon KV, Gomez D, Smith AM, Anthoney A, Verbeke CS. Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds pathology protocol (LEEPP). HPB. 2009 Feb;11(1):18–24. https://doi.org/10.1111/j.1477-2574.2008.00013.x.CrossRefPubMedPubMedCentral

47.

Verbeke CS, Gladhaug IP. Resection Margin involvement and tumour origin in pancreatic head cancer. Br J Surg 2012 Aug;99(8):1036–1049.

Titel: Prognostic Factors and the Role of Adjuvant Treatment in Periampullary Carcinoma: a Single-Centre Experience of 95 Patients
verfasst von: Saphalta Baghmar
Nikhil Agrawal
Guresh Kumar
Chhagan Bihari
Yashwant Patidar
Senthil Kumar
Tushar Kanti Chattopadhyay
Dipanjan Panda
Asit Arora
Viniyendra Pamecha
Publikationsdatum: 21.02.2018
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 3/2019
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-018-0058-7

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Prognostic Factors and the Role of Adjuvant Treatment in Periampullary Carcinoma: a Single-Centre Experience of 95 Patients

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Evaluating the Ability of the New Subclassification to Prognosticate Outcomes Following Hepatectomy for Patients with HBV-Related HCC

Novel Variants and Copy Number Variation in CDH1 Gene in Iranian Patients with Sporadic Diffuse Gastric Cancer

Efficacy of Docetaxel and Oxaliplatin Regimen as a Second-Line Therapy for Patients with Advanced Pancreatic Adenocarcinoma

Metachronous Hepatic Angiosarcoma Presenting as a Mimic of Recurrent Hepatocellular Carcinoma

Immunohistochemical Expression of Fatty Acid Synthase and Vascular Endothelial Growth Factor in Primary Colorectal Cancer: a Clinicopathological Study

Prognostic Factors for Operated Gallbladder Cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie